Synopsis: In this symposia, presenters will review the latest evidence informing the use of Upadacitinib in rheumatologic conditions in the context of today’s treatment landscape
Synopsis: The planned medac breakfast symposium “Improving conventional therapy for patients with rheumatoid arthritis by subcutaneous MTX” will elaborate on the therapeutic strategies in the
Synopsis: The purpose of this symposium is to outline the paradigm shift in understanding the pathophysiology and new treatments strategy in SLE/Lupus. Agenda: Chairperson: Prof.
Synopsis: Information coming soon Food inclusions: TBA Agenda: Chairperson: Prof Yuko Kaneko TBA mins Welcome Remarks: Introduction TBA mins The utility of the collaboration of
Ozoralizumab as a Novel Therapeutic Option for Rheumatoid Arthritis in a Super-Aged Society
Synopsis: Information coming soon Food inclusions: TBA Agenda: Chairperson: Dr. Kunihiro Yamaoka TBA mins Welcome Remarks: Introduction TBA mins Frontiers in targeted therapy on RANKL:
Synopsis: Information coming soon Food inclusions: TBA Agenda: Chairperson/s: Prof. Hoon-Suk Cha and Prof. Kunihiro Yamaoka TBA mins Welcome Remarks: Introduction TBA mins Etanercept: A
Synopsis: Information coming soon Food inclusions: TBA Agenda: Chairperson: Roger Levy TBA mins Introduction – SLE/LN in Asia : our current challenges Prof. Yoshiya Tanaka
Synopsis: It is 15 years since the first Treat-to-Target recommendations in rheumatoid arthritis (RA) were published. In 2025, this treatment strategy for the management of
Synopsis: Treatment of rheumatoid arthritis has dramatically changed by the appearance of molecular target drugs, and the treatment option with JAK inhibitors had a large
From key date reminders, abstract closures, program release updates, and speaker announcements, the best place to stay across APLAR Congress information is with the official congress mailing list.
You can opt out at anytime.
If you are translating this website, phrase based translation is used and may not be completely accurate.
